Healthcare Industry News: Neurostimulation
News Release - July 26, 2006
Boston Scientific Announces Treatment of 5,000th Chronic Pain Patient with its Innovative Neuromodulation TechnologyPrecision(TM) SCS System, the first and smallest rechargeable system, achieves rapid adoption
NATICK, Mass., July 26 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) announced today that 5,000 patients with severe chronic pain have now been treated with the Precision(TM) Spinal Cord Stimulation (SCS) System. Since the Precision System was launched nationally in March 2005, the Company has introduced the advanced neuromodulation therapy to more than 600 physicians, who use the device to provide pain relief for their patients.
"Boston Scientific's Neuromodulation Group has increased patient and physician awareness about neuromodulation therapy and given pain physicians another option for treating chronic pain patients," said Richard L. Rauck, M.D., Director of the Pain Fellowship Program and Clinical Associate Professor, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
The Precision System is the smallest and lightest rechargeable spinal cord stimulator available. The system is designed for patient comfort and convenience, featuring a cordless portable charger that enables patients to be active while charging the device. Physicians can offer pain sufferers greater control over their pain with Precision's patented Current Sculpting technology, which is intended to precisely target the pain and provide sustained pain relief.
"We are committed to improving the quality of life for our patients through technologically advanced, high-quality products," said Jeff Greiner, President of Boston Scientific's Neuromodulation Group. "Our success is a direct result of continually striving to improve our pain management technologies so patients can live with less pain, face fewer replacement surgeries, and lead more normal lives."
The Precision SCS System treats chronic pain by delivering electrical signals to the spinal cord that mask pain signals as they travel to the brain, creating a tingling sensation called paresthesia. Spinal cord stimulation is prescribed for patients with chronic pain in the limbs, trunk, and back. Patients interested in this innovative pain management technology should speak to their physicians and visit http://www.ControlYourPain.com for more information.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. The Neuromodulation Group is a global leader in the development of implantable, high-technology Neurostimulation devices that include treatments for deafness and chronic pain. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
Boston Scientific Announces Acquisition of Obsidio, Inc.
Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd